MétaCan
Menu
← Back to cohort
Record W4388601287 · doi:10.1093/eurheartj/ehad655.806

Diuretic use and outcomes in patients with HFrEF: Insights from the VICTORIA trial

2023· article· en· W4388601287 on OpenAlexaff
Justin A. Ezekowitz, Wendimagegn Alemayehu, Frank Edelmann, Piotr Ponikowski, Carolyn S.P. Lam, Cathal O’Connor, Javed Butler, Martin Homering, Stefano Corda, Ciaran J. McMullan, Cynthia M. Westerhout, Adriaan A. Voors, Robert J. Mentz, Paul W. Armstrong

Bibliographic record

VenueEuropean Heart Journal · 2023
Typearticle
Languageen
FieldMedicine
TopicHeart Failure Treatment and Management
Canadian institutionsUniversity of Alberta
FundersMerck Sharp and DohmeMerckBayer
KeywordsMedicineHeart failureHazard ratioDiureticEjection fractionRandomizationInternal medicinePopulationPlaceboFurosemideConfidence intervalDosingClinical endpointCardiologyGuidelineRandomized controlled trial

Abstract

fetched live from OpenAlex

Abstract Background In the Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial, vericiguat, compared with placebo, reduced the risk of cardiovascular death (CVD) and heart failure hospitalization (HFH) in patients enrolled shortly after a worsening heart failure (WHF) event. We examined the clinical outcomes and efficacy of vericiguat as it relates to the background use of loop diuretics in this population of patients with WHF. Methods We calculated the total daily loop diuretic dose equivalent to furosemide dosing at randomization and categorized these as <40, 40, and >40 mg total daily dose (TDD). The primary composite outcome of CVD or HFH and its components were evaluated as clinical outcomes and expressed as adjusted hazard ratios (adjHR) and 95% confidence intervals (95% CI). Post-randomization rates of change in TDD and safety were also examined. Results Of 4434 patients with diuretic dose information available at randomization, 647 (14.6%) were on <40 mg, 1633 (36.8%) were on 40 mg, and 2154 (48.6%) were on >40 mg TDD. Patient characteristics revealed those patients taking >40 mg TDD were more often in NYHA Class III/IV, diabetic, and had higher NT-proBNP, lower eGFR, less triple guideline-based HF therapy, and a higher MAGGIC risk score. The composite event rate of CVD or HFH per 100 patient years (pt-yrs) progressively increased with higher doses of diuretics: 29.8 per 100 pt-yrs for 40 mg TDD: adjHR 1.23 (95%CI 1.02-1.49); 48.1 per 100 pt-yrs for >40 mg TDD adjHR 1.50 (95%CI 1.25-1.81), relative to <40 mg TDD (22.5 per 100 pt-yrs). Results were similarly observed for the components of the composite endpoint (Figure). There was no significant interaction for the efficacy of vericiguat vs placebo for any outcome examined according to TDD at randomization (p-interaction >0.72, 0.57 and 0.64 for the primary endpoint, CVD and HFH). Diuretic dose changes post-randomization were assessed in 3684 eligible patients (followed for a median duration of 14.2 months). By treatment group, there were similar rates of up-titration (26.7 and 29.4 per 100 pt-yrs), down-titration (13.8 and 15.4 per 100 pt-yrs), and stopping of diuretic use (23.4 and 24.2 per 100 pt-yrs) observed for vericiguat and placebo groups, respectively. Conclusions The amount of loop diuretic TDD at randomization was associated with a higher risk phenotype commensurate with worse outcomes. However, the efficacy of vericiguat was preserved across this range of different loop diuretic doses used by patients with recent WHF in VICTORIA.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.009
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.013
Threshold uncertainty score0.027

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.009
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.036
GPT teacher head0.269
Teacher spread0.233 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Heart Journal→Same topicHeart Failure Treatment and Management→French-language works237,207→